|
Role of Biomarkers in Screening and Diagnosis of Ovarian |
|---|---|
| รหัสดีโอไอ | |
| Creator | Yenrudee Poomtavorn, M.D. |
| Title | Role of Biomarkers in Screening and Diagnosis of Ovarian |
| Publisher | PIMDEE Co., Ltd. |
| Publication Year | 2559 |
| Journal Title | Thai Journal of Obstetrics and Gynaecology |
| Journal Vol. | 24 |
| Journal No. | 4 |
| Page no. | 225 |
| Keyword | Ovarian cancer, screening, CA-125, HE4, ROMA |
| ISSN | 0857-6084 |
| Abstract | The overall mortality of ovarian cancer exceeds that of other gynecologic cancers owing to lackof disease-specifi symptoms. Three quarters of patients with ovarian cancer are diagnosed after thedisease has progressed to advanced stage. Thus, improvement of an effective screening tool couldresult in better prognosis and survival. To date, cancer antigen 125 (CA-125) is the most commonly used serum biomarker for detectingovarian cancer. However, the test has low sensitivity for the disease detection (50-62% for early stageepithelial ovarian cancer) and limited specifiity. Therefore, CA-125 as a single test is not recommendedfor ovarian cancer screening in asymptomatic women. CA-125 in combination with human epididymis protein 4 (HE4) and Risk of Ovarian MalignancyAlgorithm (ROMA) is becoming widely used in clinical practice for the evaluation of adnexal masses.Clinical examination, transvaginal ultrasonography (TVS) and serum biomarkers (ROMA) moreeffectively classify the patients into low and high risk of ovarian malignancy. The classifiation allowsto direct the patients to appropriate management by gynecologic oncologists, and thus the survivalrate could be improved. Role of serum biomarkers as the screening and diagnosis of ovarian cancer is described in thisreview. |
